C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer

2005 ◽  
Vol 96 (3) ◽  
pp. 441-441
Author(s):  
S. Asad Abedin
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Metastatic Disease ◽  
Specific Antigen ◽  
C Reactive Protein ◽  
Reactive Protein

C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer

2005 ◽  
Vol 95 (7) ◽  
pp. 961-962 ◽  
Author(s):  
Steven Lehrer ◽  
Edward J. Diamond ◽  
Boris Mamkine ◽  
Michael J. Droller ◽  
Nelson N. Stone ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Prostate Specific Antigen ◽  
Metastatic Disease ◽  
Specific Antigen ◽  
C Reactive Protein ◽  
Reactive Protein

scholarly journals Changes in the rate of PSA progression and the level of alkaline phosphatase during high dose vitamin C treatment of patients with prostate cancer

2017 ◽  
Vol 7 (7) ◽  
pp. 511
Author(s):  
Nina Mikirova ◽  
Ronald Hunninghake
Keyword(s):  
Prostate Cancer ◽  
Alkaline Phosphatase ◽  
Vitamin C ◽  
Cancer Patients ◽  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
High Dose ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
High Dose Vitamin

Introduction: Intravenously administered vitamin C (IVC) may have anti-cancer and anti-inflammatory properties. Many studies demonstrated evidence of a good safety profile of IVC treatments and improvement of the quality of life in cancer patients. IVC has been proposed as a treatment for cancer as an adjuvant in conjunction with other therapies. To investigate high dose ascorbic acid potential in treating prostate cancer, a retrospective study was conducted using clinical data from the Riordan Clinic database (1994-2015).Methods: We collected data, when available, on the following patient characteristics at diagnosis and during the courses of IVC therapy: age, tumor stage, Gleason score, serum prostate specific antigen (PSA) and alkaline phosphatase (ALP) levels, and location of metastases. In particular, PSA, ALP, and C-reactive protein (CRP) levels are analyzed in prostate cancer patients given IVC therapy during several years. Results: We found that PSA, CRP, and ALP correlate with tumor staging as measured by Gleason scores. Moreover, peak plasma ascorbate levels attained during the patients first IVC infusions are reduced in patients with elevated PSA and CRP levels. Tracking the changes in PSA and ALP with time in patients for whom data are available indicates that the rate of increase in these variables over time can be reduced by incorporating IVC therapy and by increasing the frequency of IVC treatments.Conclusion:  There appeared to be a relation between the frequency of IVC treatments and the rate of PSA change, with PSA rate of growth decreasing as the frequency of IVC increases.  Further research into the use of IVC in prostate cancer patients is warranted.Key words: High dose vitamin C, prostate cancer, prostate specific antigen, alkaline phosphatase, C-reactive protein. 

scholarly journals Insight into infection-mediated prostate damage: Contrasting patterns of C-reactive protein and prostate-specific antigen levels during infection

The Prostate ◽  
2017 ◽  
Vol 77 (13) ◽  
pp. 1325-1334 ◽  
Author(s):  
Melissa Milbrandt ◽  
Anke C. Winter ◽  
Remington L. Nevin ◽  
Ratna Pakpahan ◽  
Gary Bradwin ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Insight Into

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

1999 ◽  
Vol 17 (11) ◽  
pp. 3461-3467 ◽  
Author(s):  
Glenn J. Bubley ◽  
Michael Carducci ◽  
William Dahut ◽  
Nancy Dawson ◽  
Danai Daliani ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trials ◽  
Prostate Specific Antigen ◽  
Phase Ii ◽  
Metastatic Disease ◽  
Specific Antigen ◽  
Consensus Conference ◽  
End Point ◽  
Phase Ii Clinical Trials ◽  
Androgen Independent

PURPOSE: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in normal and neoplastic prostate cells. For patients with metastatic disease, changes in PSA will often antedate changes in bone scan. Furthermore, many but not all investigators have observed an association between a decline in PSA levels of 50% or greater and survival. Since the majority of phase II clinical trials for patients with androgen-independent prostate cancer (AIPC) have used PSA as a marker, we believed it was important for investigators to agree on definitions and values for a minimum set of parameters for eligibility and PSA declines and to develop a common approach to outcome analysis and reporting. We held a consensus conference with 26 leading investigators in the field of AIPC to define these parameters. RESULT: We defined four patient groups: (1) progressive measurable disease, (2) progressive bone metastasis, (3) stable metastases and a rising PSA, and (4) rising PSA and no other evidence of metastatic disease. The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials. We propose that investigators report at a minimum a PSA decline of at least 50% and this must be confirmed by a second PSA value 4 or more weeks later. Patients may not demonstrate clinical or radiographic evidence of disease progression during this time period. Some investigators may want to report additional measures of PSA changes (ie, 75% decline, 90% decline). Response duration and the time to PSA progression may also be important clinical end point. CONCLUSION: Through this consensus conference, we believe we have developed practical guidelines for using PSA as a measurement of outcome. Furthermore, the use of common standards is important as we determine which agents should progress to randomized trials which will use survival as an end point.

Epidemiological association between C-reactive protein and prostate-specific antigen

Cancer ◽  
2009 ◽  
Vol 115 (5) ◽  
pp. 1132-1132 ◽  
Author(s):  
Giuseppe Lippi ◽  
Martina Montagnana ◽  
Gian Cesare Guidi
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Epidemiological Association

scholarly journals The Significance of Plasma C-reactive Protein in Patients With Elevated Serum Prostate-specific Antigen Levels

2010 ◽  
Vol 21 (2) ◽  
pp. 88-92 ◽  
Author(s):  
Chang-Chi Chang ◽  
Alex T.L. Lin ◽  
Kuang-Kuo Chen ◽  
Hsiao-Jen Chung ◽  
Shyh-Chyi Chang
Keyword(s):  
Prostate Specific Antigen ◽  
Specific Antigen ◽  
Elevated Serum ◽  
C Reactive Protein ◽  
Serum Prostate Specific Antigen ◽  
Reactive Protein

Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 5004-5004
Author(s):  
Edmund Qiao ◽  
Nikhil V. Kotha ◽  
Vinit Nalawade ◽  
Alexander Qian ◽  
Rohith S. Voora ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
African American ◽  
Prostate Specific Antigen ◽  
Metastatic Disease ◽  
Specific Antigen ◽  
Health Administration ◽  
Grade Group ◽  
Psa Screening ◽  
Group 4 ◽  
Observation Period

5004 Background: African-American (AA) men are substantially more likely to present with lethal prostate cancer (PCa) at younger ages than non-Hispanic White men. Despite this disparity, AA men are poorly represented in the prostate-specific antigen (PSA) screening studies on which evidence-based PCa screening guidelines are based. This limits proper PSA screening guidance for AA men, especially for those younger than 55. We examined associations of PSA screening intensity with disease severity at diagnosis and prostate cancer-specific mortality (PCSM) in AA men < 55 years of age. Methods: The earliest recommended age to begin discussion of PSA screening is 40 years. We identified AA men aged 40-55 years, diagnosed with PCa from 2004 to 2017 within the Veterans Health Administration. PSA screening was identified using procedural codes. Screening intensity was defined as percentage of years screened within the pre-diagnostic observation period. This included up to 5 years prior to diagnosis. Multivariable logistic regression assessed the influence of PSA screening intensity on metastatic disease at diagnosis. Lead-time correction using published screening-dependent lead times was performed. PCSM was evaluated using Fine-Gray regression and non-cancer death as a competing event. Additional analysis was performed stratifying PSA screening into ‘High’ and ‘Low’ groups centered on the mean. Results: The cohort included 4,654 AA men at a mean age of 51.8 years with mean PSA screening rate of 53.2%. The pre-diagnostic observation period ranged from 1 to 5 years (median = 5 years). Median follow-up was 7 years. At diagnosis, there was a higher prevalence of Gleason sum ≥ 8 (Grade Group ≥ 4) and metastatic disease in the ‘Low’ group compared with the ‘High’ group ([Gleason sum ≥ 8 (Grade Group ≥ 4)]: 18.6% vs. 14.4%, p < 0.01; Metastatic disease at diagnosis: 3.7% vs. 1.4%, p < 0.01). Increased PSA screening intensity was associated with significantly reduced odds of metastatic disease at diagnosis (odds ratio: 0.61, 95% confidence interval (CI) = [0.47-0.81], p < 0.01) and decreased risk of PCSM (sub-distribution hazard ratio: 0.75, 95% CI = [0.59-0.95], p = 0.02). Conclusions: In this large national cohort of AA men aged 40 to 55 years, PSA screening increased intensity was associated with decreased risk of lethal disease and metastases at time of diagnosis and decreased PCSM. These data support the hypothesis that PSA screening and early prostate cancer detection may improve outcomes in younger AA men.

Sign in / Sign up

Export Citation Format

Share Document